BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business for $15 Million
核心洞察
BioStem Technologies completed the acquisition of BioTissue Holdings (搜索)' surgical and wound care business for $15 million upfront, with potential additional payments up to $25 million based on regulatory and commercial milestones.
The acquisition includes the Neox (搜索)® and Clarix (搜索)® product lines, a nationwide sales force, and GPO contracts, expanding BioStem's reach into hospital-based acute wound care (搜索) markets.
The acquired assets generated approximately $29 million in sales in 2025 and are expected to contribute positive EBITDA for BioStem in 2026.
BioStem Technologies has completed its acquisition of BioTissue Holdings (搜索)' surgical and wound care business in a strategic transaction valued at $15 million upfront, with potential additional payments of up to $25 million tied to regulatory and commercial milestones. The deal positions BioStem to expand its presence in the acute wound care (搜索) market while allowing BioTissue to concentrate exclusively on ocular therapeutics.
Strategic Acquisition Details
Under the definitive asset purchase agreement, BioStem acquired exclusive rights to BioTissue's Neox (搜索)® and Clarix (搜索)® product lines, along with the associated commercial infrastructure. The transaction includes a nationwide network of direct sales representatives and independent sales agents, as well as prominent Group Purchasing Organization (GPO) contracts that provide immediate access to hospital inpatient and outpatient care settings.
The acquired assets generated approximately $29 million in sales in 2025 and are expected to contribute positive EBITDA for BioStem in 2026. Post-closing, BioStem's cash and restricted cash balance stands at approximately $16 million.
"This acquisition is a natural strategic fit that underscores BioStem's commitment to leading the field of advanced wound care," said Jason Matuszewski, CEO and Chairman of BioStem. "It provides an immediate foothold in hospital-based applications and expands our technology portfolio with an additional platform designed to optimize the preservation of both placental and umbilical tissue allografts."
Commercial Integration and Leadership
BioStem has promoted industry veteran Barry Hassett to Chief Commercial Officer to lead the newly combined commercial team. Hassett brings over 25 years of industry experience, including five years with BioTissue where he served as Vice President of Marketing and led the initial development of both the surgical and wound care business and ophthalmic portfolio.
The integration significantly expands BioStem's internal commercial organization, creating direct pathways into new markets including acute surgical wounds, burns (搜索), and soft-tissue repair segments. BioTissue's surgical sales team and key support staff will join BioStem's commercial organization, while BioTissue will continue manufacturing these products for BioStem.
BioTissue's Strategic Refocus
The divestiture allows BioTissue to concentrate its commercial strategy on advancing interventional therapies for acute and chronic ocular surface conditions (搜索). The company will focus on its ocular product portfolio, including Prokera (搜索)®, CAM360 AmnioGraft (搜索)™, AmnioGraft®, and AmnioGuard (搜索)®, while prioritizing product innovation, professional education, and comprehensive customer support for the eye care market.
"This divestiture is a catalyst for our next chapter, one focused squarely on eye care innovation," said Ted Davis, President and CEO of BioTissue. "With a streamlined portfolio and dedicated resources, we are poised to deliver breakthrough solutions and support to our ocular customers and their patients."
Technology Platforms and Market Position
Both companies leverage proprietary processing technologies for their regenerative medicine products. BioStem utilizes its BioRetain® processing method, designed to optimize retention of structural and molecular properties of native tissue, while BioTissue employs its CryoTek® cryopreservation technology to maintain tissue structural and functional integrity.
BioStem's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB), with systems established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). The company's portfolio includes AmnioWrap2 (搜索)™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, AMERICAN AMNION (搜索)™, and AMERICAN AMNION™ AC.
Since its inception, clinicians have performed over 1 million procedures with BioTissue's products, supported by over 420 peer-reviewed publications. BioTissue continues advancing multiple Investigational New Drug (IND) clinical trials as it pursues Biologic License Applications (BLAs) for products addressing unmet clinical needs.